Impaired CD4+ T-cell restoration in the small versus large intestine of HIV-1-positive South Africans receiving combination antiretroviral therapy

Journal of Infectious Diseases

Volumn 208, Issue 7, 2013, Pages 1113-1122

  Cassol, Edana ^a,b,c   Malfeld, Susan ^c,g   Mahasha, Phetole ^c,g   Bond, Robert ^d   Slavik, Tomas ^e   Seebregts, Chris ^h   Poli, Guido ^i,j   Cassol, Sharon ^c,g   Van Der Merwe, Schalk W ^c,d,g   Rossouw, Theresa ^f  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Medical Research Council Unit for Inflammation and Immunity   (Colombia)

^d Hepatology and Gastrointestinal Research Laboratory   (United States)

^e Ampath Trust   (South Africa)

^f UNIVERSITY OF PRETORIA   (South Africa)

^g NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^h SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

ⁱ SAN RAFFAELE HOSPITAL   (Italy)

^j VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

more..

Author keywords

Africa; antiretroviral therapy; CD4 reconstitution; HIV 1; immune activation; intestine

Indexed keywords

EFAVIRENZ; LAMIVUDINE PLUS STAVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BLOOD; CD38+ CD8+ T LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC DIARRHEA; CLINICAL ARTICLE; COLITIS; COLON; CONTROLLED STUDY; DUODENUM; ENTERITIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; ILEUM; INTESTINE BIOPSY; JEJUNUM; MALE; MIDDLE AGED; PRIORITY JOURNAL; SOUTH AFRICA; T LYMPHOCYTE ACTIVATION; VIRUS LOAD; WEIGHT REDUCTION; YOUNG ADULT; AFRICA; ANTIRETROVIRAL THERAPY; BIOPSY; CD4 RECONSTITUTION; FLOW CYTOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE ACTIVATION; IMMUNOLOGY; INTESTINE; INTESTINE MUCOSA; LARGE INTESTINE; METHODOLOGY; SMALL INTESTINE; TREATMENT OUTCOME;

AFRICA; ANTIRETROVIRAL THERAPY; CD4 RECONSTITUTION; HIV-1; IMMUNE ACTIVATION; INTESTINE;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOPSY; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; HIV INFECTIONS; HUMANS; INTESTINAL MUCOSA; INTESTINE, LARGE; INTESTINE, SMALL; MALE; MIDDLE AGED; SOUTH AFRICA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84887300950     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit249     Document Type: Article

References (48)

1. Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004; 200:749-59
2. Fukazawa Y, Miyake A, Ibuki K, et al. Small intestine CD4+ T cells are profoundly depleted during acute simian-human immunodeficiency virus infection, regardless of viral pathogenicity. J Virol 2008; 82: 6039-44
3. Mehandru SM, Poles MA, Tenner-Racz K, et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004; 200: 761-70
4. Mehandru S, Poles MA, Tenner-Racz K, et al. Mechanisms of gastrointestinal CD4+ T-cell depletion during acute and early human immunodeficiency virus type 1 infection. J Virol 2007; 81:599-612
5. Li Q, Duan L, Estes JD, et al. Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 2005; 434:1148-52
6. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-71
7. Paiardini M, Frank I, Pandrea I, et al. Mucosal immune dysfunction in AIDS pathogenesis. AIDS Rev 2008; 10:36-46
8. Brenchley JM, Douek DC. HIV infection and the gastrointestinal immune system. Mucosal Immunol 2008; 1:23-30
9. Gordon SN, Klatt NR, Bosinger SE, et al. Severe depletion of mucosal CD4+ T cells in AIDS-free simian immunodeficiency virus-infected sooty mangabeys. J Immunol 2007; 179:3026-34
10. Pandrea IV, Gautam R, Ribeiro M, et al. Acute loss of intestinal CD4+T cells is not predictive of simian immunodeficiency virus virulence. J Immunol 2007; 179:3035-46
11. Brenchley JM, Paiardini M, Knox KS, et al. Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood 2008; 112:2826-35
12. Aujla SJ, Dubin PI, Kolls JK. Th17 cells and mucosal host defense. Semin Immunol 2007; 19:377-82
13. Liang SC, Tan XY, Luxenberg DP, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006; 203:2271-9
14. Mehandru S, Poles K, Tenner-Racz P, et al. Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS Med 2006; 3:e484
15. Gazzola L, Tincati C, Bellistre GM, et al. The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: Clinical risk, immunological gaps, and therapeutic options. Clin Infect Dis 2009; 48:328-37
16. Tincati C, Biasin M, Bandera A, et al. Early initiation of highly active antiretroviral therapy fails to reverse immunovirological abnormalities in gut-Associated lymphoid tissue induced by acute HIV infection. Antivir Ther 2009; 14:321-30
17. Talal AH, Monard S, Vesanen M, et al. Virologic and immunologic effect of antiretroviral therapy on HIV-1 in gut-Associated lymphoid tissue. J Acquir Immune Defic Syndr 2001; 26:1-7
18. Guadalupe M, Reay E, Sankaran S, et al. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 2003; 77:11708-17
19. Ciccone EJ, Read SW, Mannon PJ, et al. Cyclcing of gut mucosal CD4+T cells decreases after prolonged anti-retroviral therapy and is associated with plasma LPS levels. Mucosal Immunol 2010; 3:172-81
20. Sheth PM, Chege D, Shin LY, et al. Immune reconstitution in the sigmoid colon after long-Term HIV therapy. Mucosal Immunol 2008; 1:382-8
21. National Department of Health Republic of South Africa. Clinical guidelines for the management of HIV & AIDS in adults and adolescents, 2004. http://www.sanac.org.za. Accessed May 2012
22. WHO/UNICEF/UNAIDS. Joint reporting tool on the health sector response to HIV/AIDS 2010. Geneva, Switzerland: WHO, 2010
23. Schneider T, Jahn H-U, Schmidt W, et al. Loss of CD4 T lymphocytes in patients infected with human immunodeficiency virus type 1 is more pronounced in the duodenal mucosa than in the peripheral blood. Gut 1995; 37:524-9
24. Gordon SN, Cervasi B, Odorizzi P, et al. Disruption of intestinal CD4+T cell homeostasis is a key marker of CD4+ T cell activation in HIV-infected individuals. J Immunol 2010; 185:5169-79
25. Yuki SA, Gianella S, Sinclair E, et al. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis 2010; 202:1553-61
26. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187:1534-43
27. Mavigner M, Delobel P, Cazabat M, et al. HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS One 2009; 4:e7658
28. Guadalupe M, Sankaran S, George MD, et al. Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection. J Virol 2006; 80:8236-47
29. Giorgi JV, Liu Z, Hultin LE, et al. Elevated levels of CD38+CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: Results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1993; 6:904-12
30. Chun TW, Justement JS, Sanford C, et al. Relationship between the frequency of HIV-specific CD8+ T cells and the level of CD38+CD8+ T cells in untreated HIV-infected individuals. Proc Natl Acad Sci U S A 2004; 101:2462-9
31. Nobel A, Pestano GA, Cantor H. Suppression of immune responses by CD8 cells. I. Superantigen-Activated CD8 cells induce unidirectional Fas-mediated apoptosis of antigen-Activated CD4 cells. J Immunol 1998; 160:559-65
32. Smit-McBride Z, Mattapallil JJ, Villinger F, et al. Intracellular cytokine expression in the CD4+ and CD8+ T cells from intestinal mucosa of simian immunodeficiency virus infected macaques. J Med Primatol 1998; 27:129-40
33. Schacker TW, Brenchley JM, Beilman GJ, et al. Lymphatic tissue fibrosis is associated with reduced numbers of naïve CD4+ T cells in human immunodeficiency virus type 1 infection. Clin Vaccine Immunol 2006; 13:556-60
34. Estes JD, Haase AT, Schacker TW. The role of collagen deposition in depleting CD4+ T cells and limiting reconstitution in HIV-1 and SIV infections through damage to secondary lymphoid organ niche. Semin Immunol 2008; 20:181-6
35. Schacker TW, Cavan R, Beilman GJ, et al. Amount of lymphatic tissue fibrosis in HIV infection predicts magnitude of HAART-Associated change in peripheral CD cell count. AIDS 2005; 19:2169-71
36. Estes JD, Baker JV, Brenchley JM, et al. Collagen deposition limits immune reconstitution in the gut. J Infect Dis 2008; 198:456-64
37. Kunkel EJ, Campbell JJ, Haraldsen G, et al. Lymphocyte CC chemokine receptor 9 and epithelial-Thymus expressed chemokine (TECK) expression distinguish the small intestinal compartment: Epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity. J Exp Med 2000; 192:761-8
38. Papadakis KA, Prehn J, Moreno ST, et al. CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease. Gastroenterology 2001; 121:246-54
39. Johansson-Lindbom B, Svensson M, Wurbel MA, et al. Selective generation of gut tropic T cells in gut-Associated lymphoid tissue (GALT): Requirement for GALT dendritic cells and adjuvant. J Exp Med 2003; 198:963-9
40. Mora JR, Bono MR, Manjunath N, et al. Selective imprinting of guthoming T-cells by Peyer's patch dendritic cells. Nature 2003; 424: 88-93
41. Mavigner M, Cazabat M, Dubois M, et al. Altered CD4+ T cell homing to the gut impairs mucosal immune reconstitution in treated HIVinfected individuals. J Clin Invest 2012; 122:62-9
42. Dronda R, Moreno S, Moreno A, et al. Long-Term outcomes among antiretroviral-naive human immunodeficiency virus-infected patients with small increases in CD4+ cell counts after successful virologic suppression. Clin Infect Dis 2002; 35:1005-9
43. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004; 292:251-65
44. Kaufmann GR, Furrer H, Ledergerber B, et al. Characteristics, determinants and clinical relevance of CD4 T cell recovery to <500 cells/μL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 2005; 41:361-72
45. D'Arminio Monforte A, Testori V, Adorni F, et al. CD4 cell counts at the third month of HAART may predict clinical failure. AIDS 1999; 13:1669-76
46. Asmuth DM, Ma Z-M, Mann S, et al. Gastrointestinal-Associated lymphoid tissue immune reconstitution in a randomized clinical trial of raltegravir versus non-nucleoside reverse transcriptase inhibitor-based regimens. AIDS 2012; 26:1625-34
47. Hatano HH, Hayes TL, Dahl V, et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-Treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis 2011; 203:960-8
48. Yukl SA, Shergill AK, McQuaid K, et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS 2010; 24:2451-60